Celltrion Inc (068270) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celltrion Inc (068270) has a cash flow conversion efficiency ratio of 0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩238.15 Billion ≈ $161.39 Million USD) by net assets (₩17.81 Trillion ≈ $12.07 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Celltrion Inc (068270) total market value for the company's overall valuation and market capitalisation.
Celltrion Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Celltrion Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Celltrion Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celltrion Inc ranked by their cash flow conversion efficiency. Explore Celltrion Inc (068270) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ON Semiconductor Corporation
NASDAQ:ON
|
0.064x |
|
MongoDB
NASDAQ:MDB
|
0.069x |
|
Gulf Energy Development Public Company Limited
BK:GULF
|
0.021x |
|
Nokia Oyj
HE:NOKIA
|
0.030x |
|
China Hongqiao Group Ltd
F:H0Q
|
N/A |
|
Orsted A/S
CO:ORSTED
|
0.074x |
|
Guangdong Songfa Ceramics Co
SHG:603268
|
-0.060x |
|
Hannover Rück SE
F:HNR1
|
0.128x |
Annual Cash Flow Conversion Efficiency for Celltrion Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Celltrion Inc from 2007 to 2025. View today's stock price for Celltrion Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩17.35 Trillion ≈ $11.76 Billion |
₩646.05 Billion ≈ $437.82 Million |
0.037x | -27.43% |
| 2024-12-31 | ₩17.58 Trillion ≈ $11.91 Billion |
₩901.87 Billion ≈ $611.18 Million |
0.051x | +63.56% |
| 2023-12-31 | ₩17.13 Trillion ≈ $11.61 Billion |
₩537.16 Billion ≈ $364.02 Million |
0.031x | +15424.89% |
| 2022-12-31 | ₩4.27 Trillion ≈ $2.90 Billion |
₩863.53 Million ≈ $585.20K |
0.000x | -99.91% |
| 2021-12-31 | ₩4.05 Trillion ≈ $2.74 Billion |
₩911.16 Billion ≈ $617.48 Million |
0.225x | +119.83% |
| 2020-12-31 | ₩3.43 Trillion ≈ $2.32 Billion |
₩350.75 Billion ≈ $237.70 Million |
0.102x | -37.98% |
| 2019-12-31 | ₩2.87 Trillion ≈ $1.95 Billion |
₩473.99 Billion ≈ $321.22 Million |
0.165x | +17.38% |
| 2018-12-31 | ₩2.60 Trillion ≈ $1.76 Billion |
₩364.79 Billion ≈ $247.21 Million |
0.141x | -30.28% |
| 2017-12-31 | ₩2.41 Trillion ≈ $1.63 Billion |
₩485.98 Billion ≈ $329.34 Million |
0.202x | +76.71% |
| 2016-12-31 | ₩2.20 Trillion ≈ $1.49 Billion |
₩250.89 Billion ≈ $170.02 Million |
0.114x | +166.21% |
| 2015-12-31 | ₩1.81 Trillion ≈ $1.23 Billion |
₩77.57 Billion ≈ $52.57 Million |
0.043x | -60.21% |
| 2014-12-31 | ₩1.35 Trillion ≈ $913.37 Million |
₩145.16 Billion ≈ $98.37 Million |
0.108x | -14.59% |
| 2013-12-31 | ₩1.09 Trillion ≈ $736.73 Million |
₩137.08 Billion ≈ $92.90 Million |
0.126x | +531.44% |
| 2012-12-31 | ₩1.05 Trillion ≈ $711.67 Million |
₩20.97 Billion ≈ $14.21 Million |
0.020x | -71.38% |
| 2011-12-31 | ₩899.55 Billion ≈ $609.61 Million |
₩62.76 Billion ≈ $42.53 Million |
0.070x | +61.96% |
| 2010-12-31 | ₩779.89 Billion ≈ $528.52 Million |
₩33.60 Billion ≈ $22.77 Million |
0.043x | -72.63% |
| 2009-12-31 | ₩285.67 Billion ≈ $193.60 Million |
₩44.95 Billion ≈ $30.46 Million |
0.157x | -26.10% |
| 2008-12-31 | ₩219.72 Billion ≈ $148.90 Million |
₩46.79 Billion ≈ $31.71 Million |
0.213x | +117.06% |
| 2007-12-31 | ₩26.59 Billion ≈ $18.02 Million |
₩2.61 Billion ≈ $1.77 Million |
0.098x | -- |
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for … Read more